aTyr Pharma Stock Surges on FDA Alignment for Phase 3 Sarcoidosis Trial

Shares of aTyr Pharma (NASDAQ: ATYR) surged nearly 9.8% in pre-market trading after the biotechnology company announced it has reached an alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a pivotal Phase 3 study of its lead drug candidate, efzofitimod.

FDA Greenlights Trial Protocol

aTyr Pharma, which is based in San Diego, confirmed it received feedback from the FDA regarding its planned trial for efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis, a disease with limited treatment options. The company submitted its proposed protocol in June 2026 following a Type C meeting with the agency earlier in the year. The alignment removes a key regulatory uncertainty for the drug's development path.

According to the company, the planned global study will be a randomized, double-blind, placebo-controlled trial targeting approximately 372 patients. The primary endpoint will be the change in forced vital capacity (FVC), a measure of lung function, at week 48. aTyr expects to initiate study-related activities in the fourth quarter of 2026.

In a statement, CEO Sanjay S. Shukla said the milestone "reflects the progress of our efforts to advance efzofitimod for patients with pulmonary sarcoidosis."

Ad

Market Reaction and Financial Outlook

The positive regulatory news prompted a sharp, company-specific rally, allowing ATYR shares to trade significantly higher while the broader market faced downward pressure. The move stood in contrast to major indices like the S&P 500 and Nasdaq, which were both down in pre-market trading amid concerns over rising Treasury yields.

However, investors are also weighing the financial requirements of the late-stage trial. aTyr Pharma has previously acknowledged that the Phase 3 program will require additional financing beyond its current cash reserves. The company noted it may seek funding through equity or debt offerings, partnerships, or grants, which introduces an element of execution risk to the development timeline.